PAP
JAZZ icon

Persistent Asset Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Persistent Asset Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-115
Closed -$2.35K – 406
2025
Q3 		$2.35K Buy
+115
New +$13.8K ﹤0.01% 229

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Persistent Asset Partners's JAZZ Position: Q2 2026 in Review

Persistent Asset Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 93% in Q2 2026, selling an estimated $3.23M and leaving 1,164 shares worth $280K. The position accounts for 0.08% of the portfolio, ranked #166.

Persistent Asset Partners first reported a position in JAZZ in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.01M in Q1 2026. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Persistent Asset Partners held 1,164 shares of Jazz Pharmaceuticals worth $280K as of Q2 2026.
  • Persistent Asset Partners sold 14,741 Jazz Pharmaceuticals shares in Q2 2026, an estimated $3.23M.
  • Jazz Pharmaceuticals made up 0.08% of Persistent Asset Partners's portfolio in Q2 2026, its #166 holding.
  • Persistent Asset Partners first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Persistent Asset Partners's Jazz Pharmaceuticals position peaked at $3.01M in Q1 2026.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.